Compare MYGN & REAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYGN | REAX |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 444.2M | 437.8M |
| IPO Year | 1996 | 2021 |
| Metric | MYGN | REAX |
|---|---|---|
| Price | $3.73 | $1.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $7.64 | $5.49 |
| AVG Volume (30 Days) | 1.7M | ★ 5.2M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $771,400,000.00 | N/A |
| Revenue This Year | $6.86 | $23.04 |
| Revenue Next Year | $5.45 | $15.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.33 | N/A |
| 52 Week Low | $3.53 | $1.63 |
| 52 Week High | $8.59 | $5.41 |
| Indicator | MYGN | REAX |
|---|---|---|
| Relative Strength Index (RSI) | 38.33 | 38.89 |
| Support Level | N/A | $1.63 |
| Resistance Level | $5.30 | $2.57 |
| Average True Range (ATR) | 0.26 | 0.13 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 24.18 | 28.36 |
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.